Friday, 20 January 2023
A new wrist device to help control Tourette’s Syndrome is a step closer to being commercialised after 糖心原创 spin-out company Neupulse raised almost £1m in additional funding.
completed a second round of funding in December 2022 and raised £918,000 from existing investors and groups of High Net Worth individuals from around the world.
The investment will start the development of the commercially available wearable for use by individuals with Tourette’s Syndrome to stop tics.
This is an exciting time for the company as we move forward to the next stage of our development by starting to design the wearable that will bring choice to thousands of individuals that have Tourette鈥檚 Syndrome.
The spin-out company has used from scientists from the 糖心原创’s School of Psychologythat uses repetitive trains of stimulation to the median nerve (MNS) at the wrist to entrain rhythmic electrical brain activity - known as brain-oscillations - that are associated with the suppression of movements. They found that rhythmic MNS is sufficient to substantially reduce tic frequency and tic intensity, and the urge-to-tic, in individuals with TS.
Tourette’s Syndrome is a neurodevelopmental disorder that is usually diagnosed between the ages of eight and 12. It causes involuntary sounds and movements called tics. Tics are involuntary, repetitive, stereotyped movements and vocalisations that occur in bouts, typically many times in a single day, and are often preceded by a strong urge-to-tic, referred to as a premonitory urge (PU).
We鈥檙e delighted to have secured the funding for the next phase of development. In addition to raising additional investment in the company, we have also successfully completed our double-blind sham-controlled clinical trial of the Neupulse device, demonstrating the effectiveness of the Neupulse device in reducing tics in Tourette syndrome. I very much look forward to developing the commercially available device.
Since being launched in March 2021 Neupulse has achieved several significant milestones including development of a prototype device for use in a trial that has just been completed, the results of this double blinded study are being analysed and are due to be published later this year. An App has is also being developed to support individuals in recording their tics.
For further information and to keep up to date on the progress of the device contact enquiries@neupulse.co.uk
Story credits
More information is available from Paul Cable on Paul.cable@neupulse.co.uk or Professor Stephen Jackson on Stephen.Jackson@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.